A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90 < 5 µm and Dv50< 1 µm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.